CDER Added Some Flexibility in 2007 to Inspection Site Risk Ranking Model
This article was originally published in The Gold Sheet
Executive Summary
Site risk model was tweaked to give field more flexibility on inspections
You may also be interested in...
US FDA’s Woodcock Outlines Plans For Quicker Inspection Workflow Platform, Expected Next Year
Inspection ordering and case management software launched with food program revamp will bring real time coordination between the US FDA’s inspectorate and all its centers, enabling quicker, surer deployment and better development of cases against sites found to have poor manufacturing practices.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.